These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 8976730

  • 1. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease.
    Norose K, Yano A.
    Br J Ophthalmol; 1996 Nov; 80(11):1002-8. PubMed ID: 8976730
    [Abstract] [Full Text] [Related]

  • 2. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.
    Damico FM, Cunha-Neto E, Goldberg AC, Iwai LK, Marin ML, Hammer J, Kalil J, Yamamoto JH.
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2465-71. PubMed ID: 15980237
    [Abstract] [Full Text] [Related]

  • 3. Cytokine production and helper T cell subsets in Vogt-Koyanagi-Harada's disease.
    Imai Y, Sugita M, Nakamura S, Toriyama S, Ohno S.
    Curr Eye Res; 2001 Apr; 22(4):312-8. PubMed ID: 11462171
    [Abstract] [Full Text] [Related]

  • 4. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.
    Sugita S, Takase H, Taguchi C, Imai Y, Kamoi K, Kawaguchi T, Sugamoto Y, Futagami Y, Itoh K, Mochizuki M.
    Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2547-54. PubMed ID: 16723469
    [Abstract] [Full Text] [Related]

  • 5. Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.
    Zennadi R, Abdel-Wahab Z, Seigler HF, Darrow TL.
    Cell Immunol; 2001 Jun 15; 210(2):96-105. PubMed ID: 11520076
    [Abstract] [Full Text] [Related]

  • 6. Characterization of T-cell subsets, soluble interleukin-2 receptors and interleukin-6 in Vogt-Koyanagi-Harada disease.
    Kogiso M, Tanouchi Y, Miki S, Mimura Y.
    Jpn J Ophthalmol; 1992 Jun 15; 36(1):37-43. PubMed ID: 1635294
    [Abstract] [Full Text] [Related]

  • 7. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Int J Oncol; 2008 Sep 15; 33(3):433-41. PubMed ID: 18695871
    [Abstract] [Full Text] [Related]

  • 8. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome.
    Chen L, Yang P, Zhou H, He H, Ren X, Chi W, Wang L, Kijlstra A.
    Invest Ophthalmol Vis Sci; 2008 Aug 15; 49(8):3475-82. PubMed ID: 18421089
    [Abstract] [Full Text] [Related]

  • 9. Enhanced cytotoxicity of IFN-gamma-producing CD4+ cytotoxic T lymphocytes specific for T. gondii-infected human melanoma cells.
    Yang TH, Aosai F, Norose K, Ueda M, Yano A.
    J Immunol; 1995 Jan 01; 154(1):290-8. PubMed ID: 7995948
    [Abstract] [Full Text] [Related]

  • 10. Intraepithelial lymphocytes in human gut have lytic potential and a cytokine profile that suggest T helper 1 and cytotoxic functions.
    Lundqvist C, Melgar S, Yeung MM, Hammarström S, Hammarström ML.
    J Immunol; 1996 Sep 01; 157(5):1926-34. PubMed ID: 8757311
    [Abstract] [Full Text] [Related]

  • 11. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
    Yasumura S, Weidmann E, Hirabayashi H, Johnson JT, Herberman RB, Whiteside TL.
    Int J Cancer; 1994 May 01; 57(3):297-305. PubMed ID: 8168988
    [Abstract] [Full Text] [Related]

  • 12. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease.
    Chi W, Yang P, Li B, Wu C, Jin H, Zhu X, Chen L, Zhou H, Huang X, Kijlstra A.
    J Allergy Clin Immunol; 2007 May 01; 119(5):1218-24. PubMed ID: 17335887
    [Abstract] [Full Text] [Related]

  • 13. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
    Clemons-Miller AR, Chatta GS, Hutchins L, Angtuaco EJ, Ravaggi A, Santin AD, Cannon MJ.
    Clin Cancer Res; 2001 Mar 01; 7(3 Suppl):917s-924s. PubMed ID: 11300492
    [Abstract] [Full Text] [Related]

  • 14. Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease.
    Norose K, Yano A, Wang XC, Tokushima T, Umihira J, Seki A, Nohara M, Segawa K.
    Invest Ophthalmol Vis Sci; 1994 Jan 01; 35(1):33-9. PubMed ID: 8300361
    [Abstract] [Full Text] [Related]

  • 15. Immunoregulatory effects of CD4+ T helper subsets in human melanoma.
    Lee KY, Goedegebuure PS, Linehan DC, Eberlein TJ.
    Surgery; 1995 Apr 01; 117(4):365-72. PubMed ID: 7716716
    [Abstract] [Full Text] [Related]

  • 16. Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.
    Morisaki T, Morton DL, Uchiyama A, Yuzuki D, Barth A, Hoon DS.
    Cancer Immunol Immunother; 1994 Sep 01; 39(3):172-8. PubMed ID: 7923247
    [Abstract] [Full Text] [Related]

  • 17. Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.
    Tsujitani S, Nakashima M, Watanabe T, Kaibara N, Koprowski H, Steplewski Z.
    Anticancer Res; 1995 Sep 01; 15(3):655-60. PubMed ID: 7645938
    [Abstract] [Full Text] [Related]

  • 18. IL-10 and TGF-beta immunoregulatory cytokines rather than natural regulatory T cells are associated with the resolution phase of Vogt-Koyanagi-Harada (VKH) syndrome.
    Commodaro AG, Peron JP, Genre J, Arslanian C, Sanches L, Muccioli C, Rizzo LV, Belfort R.
    Scand J Immunol; 2010 Jul 01; 72(1):31-7. PubMed ID: 20591073
    [Abstract] [Full Text] [Related]

  • 19. HLA-B-restricted, CD8+ cytolytic human T cell clones derived from a melanoma-invaded lymph node.
    Nakashima M, Watanabe T, Koprowski H, Steplewski Z.
    Hybridoma; 1996 Apr 01; 15(2):147-54. PubMed ID: 8743295
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, Parham GP, Cannon MJ.
    J Virol; 2000 May 01; 74(10):4729-37. PubMed ID: 10775611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.